Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose Escalation Study of Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT05744739 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT05744739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05744739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose Escalation Study of Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Terminated
Start date
September 29, 2023
Completion date
August 20, 2024
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia